Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Grows By 6,550.0%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 26,600 shares, a growth of 6,550.0% from the August 31st total of 400 shares. Based on an average trading volume of 116,000 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Stock Up 1.5 %

OTCMKTS:CHGCY opened at $24.54 on Wednesday. Chugai Pharmaceutical has a 52-week low of $14.05 and a 52-week high of $25.99. The stock’s 50-day simple moving average is $22.38 and its 200 day simple moving average is $19.06.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.03 billion during the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. On average, analysts expect that Chugai Pharmaceutical will post 0.78 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.